Cite
HARVARD Citation
Wolpin, B. et al. (2013). Multicenter Phase II Study of Tivozanib (AV‐951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. Oncologist. pp. 377-378. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wolpin, B. et al. (2013). Multicenter Phase II Study of Tivozanib (AV‐951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. Oncologist. pp. 377-378. [Online].